-
Mashup Score: 0EU panel backs approval of relugolix for prostate cancer - 2 year(s) ago
The approval recommendation for the GnRH receptor antagonist is based on data from the phase 3 HERO study.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 3
ASCO GU 2022 HERO trial relugolix in advanced prostate cancer examining for effect modification by patient race, Black men enrolled in the HERO trial, superior continuous suppression of testosterone to castrate levels with relugolix, relugolix HERO a once-daily oral GnRH receptor antagonist compared to leuprolide.
Source: www.urotoday.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @WallisCJD: Lots of data from the HERO trial of #relugolix at #gu22 today: - consistent results in Black men: https://t.co/7ntJFzbgUd -…
-
-
Mashup Score: 1
ASCO GU 2022 HERO trial relugolix in advanced prostate cancer examining for effect modification by patient race, Black men enrolled in the HERO trial, superior continuous suppression of testosterone to castrate levels with relugolix, relugolix HERO a once-daily oral GnRH receptor antagonist compared to leuprolide.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
RT @WallisCJD: Lots of data from the HERO trial of #relugolix at #gu22 today: - consistent results in Black men: https://t.co/7ntJFzbgUd -…
-
-
Mashup Score: 2
ASCO GU 2022 HERO trial relugolix in advanced prostate cancer examining for effect modification by patient race, Black men enrolled in the HERO trial, superior continuous suppression of testosterone to castrate levels with relugolix, relugolix HERO a once-daily oral GnRH receptor antagonist compared to leuprolide.
Source: www.urotoday.comCategories: Latest Headlines, UrologyTweet-
Lots of data from the HERO trial of #relugolix at #gu22 today: - consistent results in Black men: https://t.co/7ntJFzbgUd - quicker testosterone recovery: https://t.co/XJPVLizAtQ @urotoday
-
-
Mashup Score: 7
ASCO GU 2022 HERO trial relugolix in advanced prostate cancer examining for effect modification by patient race, Black men enrolled in the HERO trial, superior continuous suppression of testosterone to castrate levels with relugolix, relugolix HERO a once-daily oral GnRH receptor antagonist compared to leuprolide.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Efficacy and safety of #relugolix in Black men with adv #ProstateCancer: A subgroup analysis from the randomized, phase 3 #HERO study vs leuprolide. Presented by @Daniel_J_George @DukeCancer. #GU22 written coverage by @WallisCJD @UofT > https://t.co/T1EJtpehJj @ASCO https://t.co/hYLV0WY34E
-
-
Mashup Score: 0
Neeraj Agarwal, MD joins Petros Grivas, MD, PhD, sharing his clinical perspective on using relugolix in patients with advanced prostate cancer, and how this new oral treatment option fits into the prostate cancer treatment algorithm. The phase 3 HERO trial looked at patients with advanced prostate cancer, locally advanced prostate cancer, as well as metastatic prostate cancer, and patients were…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Relugolix in the Treatment of Advanced #ProstateCancer. @neerajaiims @huntsmancancer joins @PGrivasMDPhD @UW sharing his clinical perspective on the use of #relugolix in patients with advanced PCa. #WatchNow on UroToday > https://t.co/A7COjiQXK7 @Myovant #HERO @SeattleCCA https://t.co/13EXAsi4F9
-
-
Mashup Score: 0
Neeraj Agarwal, MD joins Petros Grivas, MD, PhD, sharing his clinical perspective on using relugolix in patients with advanced prostate cancer, and how this new oral treatment option fits into the prostate cancer treatment algorithm. The phase 3 HERO trial looked at patients with advanced prostate cancer, locally advanced prostate cancer, as well as metastatic prostate cancer, and patients were…
Source: UroTodayCategories: Latest Headlines, UrologyTweet-
Relugolix in the Treatment of Advanced #ProstateCancer. @neerajaiims @huntsmancancer joins @PGrivasMDPhD @UW sharing his clinical perspective on the use of #relugolix in patients with advanced PCa. #WatchNow on UroToday > https://t.co/A7COjiQXK7 @Myovant #HERO @SeattleCCA https://t.co/aZgXk9GBYE
-
-
Mashup Score: 0Transitioning Patients to an Oral GnRH Antagonist and Optimizing Patient Outcomes - Brenda Martone - 3 year(s) ago
Advanced Nurse Practitioner, Brenda Martone of Northwestern University Feinberg School of Medicine joins Alicia Morgans, MD, MPH in a discussion on operationalizing the use of the oral GnRH antagonist, relugolix, in clinical practice. They discuss the unique challenges often faced with getting an oral treatment into the patient’s hands and talk through the best practices to ensure a successful…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Transitioning patients to an oral GnRH antagonist and optimizing patient outcomes. Brenda Martone, MSN, ANP-BC, AOCNP @LurieCancer joins @CaPsurvivorship @DanaFarber to discuss operationalizing the use of #relugolix, in clinical practice. #WatchNow > https://t.co/GKMJvKwjId https://t.co/YpyS4TGEtt
-
-
Mashup Score: 1
Tom Keane, MBBCh, FRCSI, FACS, recaps the HERO Phase III Trial comparing the safety and efficacy of relugolix with leuprolide acetate in advanced prostate cancer patients. In this trial, men with advanced prostate cancer who received relugolix achieved rapid, sustained suppression of testosterone levels that were superior to that with leuprolide, with a 54% lower risk of major adverse…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
#HERO trial: Oral #relugolix for ADT in advanced #ProstateCancer. Thomas Keane, MBBCh, FRCSI, FACS @MUSChealth recaps the trial results on UroToday. #WatchNow > https://t.co/ntvLb8jYJh @NEJM @Myovant https://t.co/pVSclofi9E
-
-
Mashup Score: 0
Tom Keane, MBBCh, FRCSI, FACS, recaps the HERO Phase III Trial comparing the safety and efficacy of relugolix with leuprolide acetate in advanced prostate cancer patients. In this trial, men with advanced prostate cancer who received relugolix achieved rapid, sustained suppression of testosterone levels that were superior to that with leuprolide, with a 54% lower risk of major adverse…
Source: UroTodayCategories: Latest Headlines, UrologyTweet-
#HERO trial: Oral #relugolix for ADT in advanced #ProstateCancer. Thomas Keane, MBBCh, FRCSI, FACS @MUSChealth recaps the trial results on UroToday. #WatchNow > https://t.co/ntvLb8jYJh @NEJM @Myovant https://t.co/wLY3STnGfr
-
EU panel backs approval of relugolix for prostate cancer https://t.co/D4wiLueg8O #ProstateCancer #Relugolix #Urology #Urologist